Bharath Advanced Therapeutics (BAT) presented breakthrough preclinical data on its lead molecule targeting Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) at Cancer NEXT 2024, held on November 30, 2024, at the Nizam's Institute of Medical Sciences (NIMS), Hyderabad. The conference, jointly presented by BAT and the Federation of Asian Biotech Associations (FABA), focused on fostering collaboration and innovation in cancer treatment.
The preclinical data showcased complete tumor regression in human xenograft models, even under aggressive growth conditions, with no recurrence observed after treatment. This sets the stage for First-in-Human trials planned for late 2025. The molecule represents a potential turning point in achieving remission and improving patient outcomes for AML and CML patients, who often have limited treatment options.
Key Conference Highlights
Cancer NEXT 2024 featured scientific presentations on breakthroughs in cancer diagnostics, therapeutics, and personalized medicine. Keynote addresses were delivered by leading oncologists and biotech innovators, and roundtable discussions explored solutions for challenges in cancer care and therapeutic development.
BAT's Commitment to Cancer Innovation
"At BAT, we are driven by the mission to develop transformative cancer therapies," said Dr. Uday Saxena, Chair of Product Development at BAT. "The preclinical results we will present at Cancer NEXT 2024 underscore India's potential to lead in global cancer innovation."
Dr. Markandeya Gorantla, Founder of BAT, emphasized, "With limited treatment options for AML and CML, our approach represents a turning point in achieving remission and improving patient outcomes."
Industry Recognition
Cancer NEXT 2024 also recognized outstanding contributions to cancer research with awards sponsored by Natco Pharma, Virchow Biotech, Virupaksha Organics, and the Promoters of BAT. These awards aim to inspire and support researchers whose work is making a meaningful impact in the fight against cancer.
